ライフサイエンスコーパス: abciximab

1 alloon angioplasty versus stenting, each +/- abciximab.

2 plasty versus stenting, each with or without abciximab.

3 A + abciximab, stenting alone, or stenting + abciximab.

4 ere randomly assigned to receive acolysis or abciximab.

5 ned stenting were randomized to tirofiban or abciximab.

6 Of 181 enrolled, 92 received acolysis and 89 abciximab.

7 international U (IU)/kg alone or followed by abciximab.

8 nd tirofiban, but had the opposite effect on abciximab.

9 ssigned a bolus and infusion of tirofiban or abciximab.

10 parin and GP IIb/IIIa inhibitor therapy with abciximab.

11 pen occluded arteries (GUSTO-IV) trials with abciximab.

12 dy that recognized platelets sensitized with abciximab.

13 se tenecteplase (TNK) and half-dose TNK plus abciximab.

14 otection from major ischemic events than did abciximab.

15 y derive the greatest mortality benefit from abciximab.

16 five patients received tirofiban followed by abciximab.

17 noninferiority of tirofiban as compared with abciximab.

18 Fifteen patients received only abciximab.

19 cardial infarction in patients randomized to abciximab.

20 p = 0.003) suggests a mortality benefit with abciximab.

21 n patients received eptifibatide followed by abciximab.

22 y between two such inhibitors, tirofiban and abciximab.

23 of that rise is diminished by periprocedural abciximab.

24 cally relevant concentrations of aspirin and abciximab.

25 eeding in women was similar with and without abciximab.

26 d 16.0% to 9.9% (p<0.001) in women receiving abciximab.

27 th reduced-dose thrombolysis and concomitant abciximab.

28 2.7% to 6.5% (p<0.001) in women treated with abciximab.

29 .0% to 2.5% (p = 0.03) in women treated with abciximab.

30 but not all pharmacological properties with abciximab.

31 entional centre with half-dose reteplase and abciximab.

32 fibatide compared with patients treated with abciximab.

33 er stenting or balloon angioplasty, each +/- abciximab.

34 In vitro, increasing concentrations of abciximab (0% to 100% receptor occupancy) were tested.

35 rt) or the combination of a standard dose of abciximab (0.25 mg/kg bolus, 0.125 microg/kg per minute

36 h addition of the antibodies 7E3 and Reopro (abciximab) (10 microg/mL), accompanied by a 40% to 70% r

37 nts after PTCA, 16.5 percent after PTCA plus abciximab, 11.5 percent after stenting, and 10.2 percent

38 18 antibody had an effect similar to that of abciximab (16.5+/-0.4%).

39 vs. 4.8%, p = 0.91) and abciximab versus no abciximab (4.3% vs. 5.0%, p = 0.63).

40 incidence of gastrointestinal bleeding with abciximab (4.8% vs. 2.8%, p = 0.01).

41 d to intracoronary compared with intravenous abciximab (54.4; interquartile range: 35.1 to 78.2 vs. 3

42 hen added to VSMCs exposed to MMs and M-CSF, abciximab (7 microg/mL) significantly reduced VSMC apopt

43 %; stent/placebo, 15.8%; balloon angioplasty/abciximab, 7.6%; and stent/abciximab, 8.0% (P<0.001).

44 lloon angioplasty/abciximab, 7.6%; and stent/abciximab, 8.0% (P<0.001).

45 0/microL]) within a few hours of being given abciximab a second time showed that each had a strong im

46 nts given the fibrinogen receptor antagonist abciximab, a chimeric Fab fragment containing murine spe

47 Abciximab, a derivative of the murine mAb 7E3, protects

48 Abciximab, a platelet GP IIb/IIIa receptor inhibitor, ha

49 n angioplasty (PTCA) and abciximab versus no abciximab according to a 2-by-2 factorial design.

50 uced doses of either alteplase or reteplase, abciximab achieved 91% and 83% inhibition of 5 and 20 mi

51 tion myocardial infarction, as compared with abciximab administered immediately before the procedure

52 Whether intralesional abciximab administration and thrombus aspiration confer

53 benefit of intracoronary versus intravenous abciximab administration on myocardial damage and/or rep

54 and with aggregometry for up to 1 week after abciximab administration.

55 Ia receptor blockade in the first week after abciximab administration.

56 ry, and the frequency of stent deployment or abciximab administration.

57 xaparin before PCI and a 12-hour infusion of abciximab after PCI.

58 ded a similar level of overall protection to abciximab against the composite of death, myocardial inf

59 eplase (combination-facilitated PCI) or with abciximab alone (abciximab-facilitated PCI) would improv

60 rapy patients and one of the 15 who received abciximab alone had minor bleeding.

61 teplase plus abciximab nor facilitation with abciximab alone significantly improved the clinical outc

62 ng and embolic protection, and stenting with abciximab alone, glomerular filtration rate declined (P<

63 ys greater than or equal to that achieved by abciximab alone.

64 ban are specific for alphaIIb/beta3, whereas abciximab also exhibits cross-reactivity with the alphav

65 Patients randomized to intracoronary abciximab also had a significant reduction in absolute i

66 Abciximab and 7E3, the anti-beta(3) integrin monoclonal

67 atients are specific for murine sequences in abciximab and are capable of causing life-threatening th

68 In the Controlled Abciximab and Device Investigation to Lower Late Angiopl

69 t-PCI electrocardiograms from the Controlled Abciximab and Device Investigation to Lower Late Angiopl

70 In the Controlled Abciximab and Device Investigation to Lower Late Angiopl

71 In the Controlled Abciximab and Device Investigation to Lower Late Angiopl

72 tilized for score derivation (the Controlled Abciximab and Device Investigation to Lower Late Angiopl

73 n = 700) in two substudies of the Controlled Abciximab and Device Investigation to Lower Late Angiopl

74 The Controlled Abciximab and Device Investigation to Lower Late Angiopl

75 mg intravenous bolus), or half-dose TNK plus abciximab and either UFH (bolus 40 U/kg; infusion 7 U/kg

76 An interaction was observed between abciximab and embolic protection (P<0.05), favoring comb

77 ed models, no significant difference between abciximab and eptifibatide was observed with respect to

78 ns were also less sensitive to inhibition by abciximab and eptifibatide.

79 065 patients to intracoronary or intravenous abciximab and found similar rates of major adverse cardi

80 Treatment with abciximab and low-dose, weight-adjusted heparin during p

81 es after primary PCI are bolus intracoronary abciximab and manual aspiration thrombectomy.

82 s, early PCI facilitated by a combination of abciximab and reduced-dose reteplase was safe and effect

83 Combination therapy (abciximab and reteplase) did not reduce mortality over 1

84 e compared to those receiving combination of abciximab and reteplase.

85 Abciximab and specific inhibitors of the Mac-1 receptor

86 mposite end point for patients not receiving abciximab and the need for TVR among all patients.

87 Intralesional abciximab and thrombus aspiration may have long-term ben

88 red locally at the infarct lesion site vs no abciximab and to manual aspiration thrombectomy vs no th

89 locally at the infarct lesion site versus no abciximab and to manual thrombus aspiration versus no as

90 et glycoprotein IIb/IIIa receptor inhibitor (abciximab) and a half dose of a plasminogen activator (r

91 le for the lack of a consistent benefit with abciximab, and describes future directions for clinical

92 Doses of eptifibatide, abciximab, and tirofiban that inhibited platelet aggrega

93 had an additive effect on the inhibition by abciximab (anti-glycoprotein (GP) IIb/IIIa antibody).

94 ibody 7E3 from which the murine sequences in abciximab are derived; and (2) the "normal" antibodies c

95 ocytopenia so that the beneficial effects of abciximab are not lost by premature termination of thera

96 The use of abciximab as an adjunct during complex infrainguinal art

97 rial, we compared early and late outcomes by abciximab assignment among 2082 patients randomized in a

98 ients with STEMI treated by thrombolysis and abciximab at a non-interventional hospital to immediate

99 gned patients to receive either tirofiban or abciximab before undergoing percutaneous coronary revasc

100 Abciximab binds alpha(IIb)beta(3) on platelets and alpha

101 Abciximab binds Mac-1 (CD11b/CD18) on MMs.

102 benefits of intracoronary versus intravenous abciximab bolus administration on infarct size and reper

103 s randomized to intracoronary or intravenous abciximab bolus at the time of primary PCI.

104 The intracoronary abciximab bolus did not reduce the primary endpoint in p

105 Administration of an intracoronary abciximab bolus during primary percutaneous coronary int

106 protein IIb/IIIa (GP IIb/IIIa) blockade with abciximab bolus plus 12-h infusion reduces mortality aft

107 tients shows a mortality benefit provided by abciximab bolus plus 12-h infusion.

108 ghty patients each had received a placebo or abciximab bolus plus a 12-hour infusion.

109 c patients, intracoronary versus intravenous abciximab bolus was associated with a significantly redu

110 isk for developing thrombocytopenia if given abciximab by screening for antibodies that recognize 7E3

111 Administered after tirofiban, abciximab caused a significant further decline in platel

112 Administered after eptifibatide, abciximab caused a significant further reduction in plat

113 ling; pharmacological therapy (cyclosporine, abciximab, clopidogrel, tirofiban, erythropoietin, throm

114 b or placebo (p = 0.27 for interaction among abciximab/clopidogrel and placebo/clopidogrel treatment

115 IgG antibodies reactive with abciximab-coated platelets were also found in 77 (74%) o

116 Fab fragments and, although they react with abciximab-coated platelets, appear not to cause signific

117 of AET was reduced in patients who received abciximab combination therapy compared with thrombolytic

118 this enhanced level of platelet activation, abciximab, combined with a reduced-dose thrombolytic, in

119 of both major and minor bleeding events with abciximab compared with men, major bleeding in women was

120 Patients randomized to intracoronary abciximab compared with no abciximab had a significant r

121 r of follow-up, treatment with intralesional abciximab compared with no abciximab was associated with

122 iabetic patients randomized to intracoronary abciximab compared with those randomized to intravenous

123 Coronary stenting with abciximab, compared with stenting alone or balloon angio

124 her ligands mimicking small molecular drugs, abciximab cross-reacts with integrin alphavbeta3 and alp

125 ilable: the monoclonal antibody Fab fragment abciximab, cyclic peptides based on the Arg-Gly-Asp (RGD

126 Abciximab decreases the mortality of diabetic patients t

127 andomized in a 2x2 factorial design to bolus abciximab delivered locally at the infarct lesion site v

128 x 2 factorial design to bolus intracoronary abciximab delivered locally at the infarct lesion site v

129 significantly reduced by bolus intracoronary abciximab delivered to the infarct lesion site but not b

130 However, abciximab does not have proven efficacy in medical manag

131 in a placebo-controlled, randomized trial of abciximab during angioplasty.

132 ze the effects of repeated administration of abciximab during intervention.

133 valuated the clinical efficacy of adjunctive abciximab during mechanical or pharmacologic reperfusion

134 s have evaluated the efficacy of concomitant abciximab during mechanical reperfusion therapy in the s

135 ng 4,809 patients randomized to tirofiban or abciximab during PCI with stent placement were compared

136 s with acute STEMI were allocated to receive abciximab either in the ambulance (ambulance group, n=12

137 or IIb/IIIa receptor antagonists (tirofiban, abciximab, eptifibatide); or DTIs (r-hirudin, bivalirudi

138 s of glycoprotein (GP) IIb/IIIa antagonists (abciximab, eptifibatide, and tirofiban) and other inhibi

139 Three such alphaIIbbeta3 antagonists, abciximab, eptifibatide, and tirofiban, received Food an

140 Administration of abciximab, eptifibatide, or tirofiban at doses recommend

141 ercutaneous coronary intervention to receive abciximab, eptifibatide, or tirofiban at doses used in t

142 Our objective was to determine whether abciximab, eptifibatide, or tirofiban inhibited ligand b

143 r without fixation; (3) the slow off-rate of abciximab exposes only a small proportion of unblocked G

144 ombination-facilitated PCI (43.9%) than with abciximab-facilitated PCI (33.1%) or primary PCI (31.0%;

145 ts in the combination-facilitated PCI group, abciximab-facilitated PCI group, and primary-PCI group,

146 on-facilitated PCI) or with abciximab alone (abciximab-facilitated PCI) would improve outcomes in pat

147 toms to receive combination-facilitated PCI, abciximab-facilitated PCI, or primary PCI.

148 rinogen receptor antagonists eptifibatide or abciximab failed to become potentiated by heparin, demon

149 ters in the United States who were receiving abciximab for at least a second time during percutaneous

150 equire PCI and may benefit from switching to abciximab, for which long-term benefits have been report

151 oved the clinical outcomes, as compared with abciximab given at the time of PCI, in patients with ST-

152 an group than among the 2411 patients in the abciximab group (7.6 percent vs. 6.0 percent; hazard rat

153 ith 468 (5.6%) in the combined reteplase and abciximab group (odds ratio 0.95 [95% CI 0.83-1.08], p=0

154 in interleukin-6 levels was 76% less in the abciximab group (P<0.001); and the rise in tumor necrosi

155 farction between the tirofiban group and the abciximab group was significant (6.9 percent and 5.4 per

156 ned, however; aggregate 1-year costs for the abciximab group were 1244 dollars greater than for stand

157 ongestive heart failure in the intracoronary abciximab group.

158 significant differences between placebo and abciximab groups.

159 etween the intracoronary and the intravenous abciximab groups.

160 to intracoronary abciximab compared with no abciximab had a significant reduction in 30-day infarct

161 or balloon angioplasty, each with or without abciximab, had CK levels determined at baseline and at 8

162 e percutaneous coronary intervention trials, abciximab has been more efficacious than the other paren

163 Abciximab has well-established clinical benefits in nume

164 Abciximab has well-established clinical benefits in perc

165 ofiban and 345 (14.3%) patients who received abciximab (hazard ratio 1.04, 95% CI 0.90-1.21; p=0.591)

166 independently reduced by balloon angioplasty/abciximab (hazard ratio, 0.51; P<0.001) and stent/abcixi

167 imab (hazard ratio, 0.51; P<0.001) and stent/abciximab (hazard ratio, 0.60; P=0.02) but was not affec

168 oland were treated with half-dose reteplase, abciximab, heparin, and aspirin, and randomly assigned t

169 The aim of the AIDA STEMI (Abciximab i.v. Versus i.c. in ST-elevation Myocardial In

170 Administration of abciximab immediately after tirofiban or eptifibatide th

171 ting and the glycoprotein IIb/IIIa inhibitor abciximab improve outcomes for patients undergoing prima

172 h STEMI, the administration of intracoronary abciximab improved the effectiveness of primary PCI comp

173 andomized to stenting with either placebo or abciximab in addition to aspirin and heparin.

174 Use of abciximab in combination with administration of thrombol

175 fective compared to that of selective use of abciximab in only those patients requiring percutaneous

176 t with tirofiban or eptifibatide followed by abciximab in patients undergoing percutaneous coronary i

177 ffect of reteplase alone with reteplase plus abciximab in patients with acute myocardial infarction.

178 vestigate whether in-ambulance initiation of abciximab in patients with ST-segment elevation myocardi

179 Early ambulance administration of abciximab in STEMI did not improve either STR or TIMI fl

180 ho received thrombolytic monotherapy without abciximab in the TIMI 4, 10A, 10B, and 14 trials (n=1662

181 is article provides an update of the role of abciximab in the treatment for ACS based on the results

182 The cost-effectiveness of abciximab in this setting is uncertain and depends prima

183 a platelet glycoprotein IIb/IIIa inhibitor, abciximab, in a 2x2 factorial design.

184 Other documented effects of abciximab include acute dethrombosis, reduction of throm

185 Compared with standard anticoagulation, abciximab increased initial procedural costs by 1122 dol

186 The alphaIIbbeta3 antagonist, abciximab, inhibited binding without affecting the unbin

187 widely used integrin alphaIIbbeta3 inhibitor abciximab is a chimeric mouse/human antibody that induce

188 s whether the use of eptifibatide instead of abciximab is associated with a difference in outcomes of

189 Abciximab is presently under evaluation in the treatment

190 h stenting alone or balloon angioplasty with abciximab, is associated with improved survival and is a

191 ed controlled trials suggest that the use of abciximab may be associated with a survival advantage in

192 Ib/IIIa, avbeta3, and alphaMbeta2 receptors, abciximab may reduce inflammatory processes.

193 egional consortium and who were treated with abciximab (n = 729) or with eptifibatide (n = 2,812).

194 imab (n=528), stenting (n=512), and stenting+abciximab (n=524).

195 d to balloon angioplasty (PTCA; n=518), PTCA+abciximab (n=528), stenting (n=512), and stenting+abcixi

196 n=8260) or half-dose reteplase and full-dose abciximab (n=8328).

197 erapy in TIMI 14 (low-dose thrombolytic plus abciximab, n=732) were compared with patients who receiv

198 ther facilitation of PCI with reteplase plus abciximab nor facilitation with abciximab alone signific

199 plasty + abciximab, stenting, and stenting + abciximab, normal myocardial perfusion was restored in 1

200 ve difference in TVR rates (ie, no effect of abciximab on reducing restenosis).

201 f performed; or 2) wait, and selectively use abciximab only in patients who ultimately undergo PCI.

202 vitro inhibition of platelet aggregation by abciximab or correlate with clinical events.

203 bolus) with planned Gp IIb/IIIa inhibition (abciximab or eptifibatide) (n = 3011).

204 bolus), with planned Gp IIb/IIIa inhibition (abciximab or eptifibatide).

205 pretreatment, irrespective of assignment to abciximab or placebo (p = 0.27 for interaction among abc

206 randomly assigned to adjunctive therapy with abciximab or placebo at the beginning of the study.

207 planned stenting were randomized to receive abciximab or tirofiban.

208 [alone or in combination], eptifibatide, or abciximab) or anticoagulants (antithrombin dabigatran et

209 er integrins, the pharmacodynamic profile of abciximab, or other effects.

210 cyclic RGD peptide, the monoclonal antibody abciximab, or the alpha v beta 3-specific cyclic peptide

211 01 to 1.57, demonstrating the superiority of abciximab over tirofiban; P=0.038).

212 enting, and 10.2 percent after stenting plus abciximab (P<0.001).

213 ed survival were assignment to stenting with abciximab (p=0.027) and greater preprocedural stenosis (

214 Del-1 (P=0.027) and by annexin A5 (P=0.027), abciximab (P=0.027), a monoclonal antibody to integrin a

215 the tirofiban-RESTORE regimen compared with abciximab (P=0.028) and eptifibatide regimens (P=0.0001)

216 t 30 days was 25% with acolysis and 12% with abciximab (P=0.036), attributable mainly to a greater fr

217 fter PTCA to 5.2 percent after stenting plus abciximab, P<0.001).

218 ieved in 63% of acolysis patients and 82% of abciximab patients (P=0.008).

219 d in 53.8% of acolysis patients and 73.1% of abciximab patients (P=0.014).

220 ntion (PCI) preceded by early treatment with abciximab plus half-dose reteplase (combination-facilita

221 Aspirin plus ticlopidine, as well as abciximab, protected 45%-88% of animals against S. gordo

222 r the combination of half-dose reteplase and abciximab provides any propitious benefits over standard

223 women in the CADILLAC trial, the addition of abciximab reduced 30-day TVR without increasing bleeding

224 facilitating accelerated hospital discharge, abciximab reduced length of stay by approximately 0.6 da

225 Abciximab reduced the occurrence of platelet-rich emboli

226 olytic monotherapy, combination therapy with abciximab reduces AET, which in turn is associated with

227 nti-platelet and anti-thrombotic activities, abciximab reduces thrombus formation and hence minimizes

228 The abciximab regimen, however, showed increasingly varied a

229 Platelet glycoprotein IIb/IIIa blockade with abciximab (ReoPro) improves the clinical outcomes of per

230 vation or adhesion (clopidogrel (Plavix) and abciximab (ReoPro), respectively).

231 ed in the United States and other countries: abciximab (ReoPro; the Fab fragment of a chimeric human-

232 randomized to intracoronary abciximab vs no abciximab, respectively, and in 174 and 179 patients ran

233 haIIbbeta3 receptor inhibitors cangrelor and abciximab, respectively, both in vitro--by incubating th

234 and 42.7% assigned to PTCA alone and PTCA + abciximab, respectively.

235 p = 0.94) of men treated with placebo versus abciximab, respectively.

236 = 0.003) of men treated with placebo versus abciximab, respectively.

237 with acute coronary syndromes (ACS; n=3025), abciximab resulted in lower rates of myocardial infarcti

238 domly assigned to undergo PTCA alone, PTCA + abciximab, stenting alone, or stenting + abciximab.

239 nts randomized to angioplasty, angioplasty + abciximab, stenting, and stenting + abciximab, normal my

240 the net incremental baseline cost of these 2 abciximab strategies was $583 with low-dose weight-adjus

241 e protein was 32% less in patients receiving abciximab than placebo (P=0.025); the rise in interleuki

242 noninferiority of tirofiban as compared with abciximab, the findings demonstrated that tirofiban offe

243 Ia inhibitors have shown benefit in ACS, but abciximab, the more expensive GP IIb/IIIa inhibitor, may

244 the MultiLink stent (512), or stenting plus abciximab therapy (524).

245 undergo PTCA alone (518 patients), PTCA plus abciximab therapy (528), stenting alone with the MultiLi

246 rosis factor-alpha levels was 100% less with abciximab therapy (P=0.112).

247 e incidence of pseudothrombocytopenia during abciximab therapy administered for percutaneous coronary

248 nosis at 90 minutes was also improved in the abciximab therapy group both in patent arteries (64.6+/-

249 centers, stent implantation (with or without abciximab therapy) should be considered the routine repe

250 rom 14 patients undergoing PTCA who received abciximab therapy, ticlopidine therapy, or both treatmen

251 Treatment with intralesional abciximab, thrombus aspiration, or both therapies compar

252 e current study was to determine if combined abciximab/ticlopidine therapy inhibits arterial thrombos

253 Of the 3 treatments, combined abciximab/ticlopidine therapy produced the most consiste

254 (1) dissociation of GP IIb/IIIa antagonists (abciximab, tirofiban, eptifibatide, or xemilofiban) from

255 Thus, addition of 3 microg/mL abciximab to 1.0 anti-IIa/Xa U/mL heparin and to 1.0 ant

256 The addition of abciximab to primary stenting significantly reduced the

257 5% confidence intervals [CI]: 1.7%, 2.5%) of abciximab-treated patients and in 0.6% of placebo-treate

258 nia occurred in 3.7% (95% CI: 3.2%, 4.2%) of abciximab-treated patients and in 1.8% (95% CI: 1.3%, 2.

259 0.89; P:=0.010) in both placebo-treated and abciximab-treated patients.

260 icantly (18.4% for controls versus 16.9% for abciximab-treated patients; relative risk, 0.92; 95% CI,

261 y and abciximab treatment (n=1052) versus no abciximab treatment (n=1030).

262 l of primary stenting versus angioplasty and abciximab treatment (n=1052) versus no abciximab treatme

263 Abciximab treatment alone inhibited mural thrombosis for

264 Abciximab treatment did not affect the composite end poi

265 Adjunctive abciximab treatment during primary percutaneous coronary

266 Abciximab treatment was associated with a significant re

267 rombosis also was significantly reduced with abciximab treatment.

268 significant interaction between stenting and abciximab treatment.

269 y reocclusion at 7 months were unaffected by abciximab treatment.

270 ent with randomized clinical trials of first abciximab treatment.

271 A total of 564 patients (274 in abciximab/UFH group vs. 290 in bivalirudin group) were e

272 val model, the risk ratio for mortality with abciximab use compared with placebo was 0.642 (95% confi

273 ents with ACS undergoing stent implantation, abciximab use compared with tirofiban results in greater

274 The beneficial reduction in mortality with abciximab use in diabetics classified as insulin-requiri

275 In adjusted models, contraindicated abciximab use in patients with thrombocytopenia (hazard

276 Contraindicated abciximab use was not significantly associated with 30-d

277 nd 5.7 percent (P=0.01), both independent of abciximab use.

278 us angioplasty (4.5% vs. 4.8%, p = 0.91) and abciximab versus no abciximab (4.3% vs. 5.0%, p = 0.63).

279 enting versus balloon angioplasty (PTCA) and abciximab versus no abciximab according to a 2-by-2 fact

280 o the combination of half-dose reteplase and abciximab versus those randomized to reteplase.

281 and 172 patients randomized to intracoronary abciximab vs no abciximab, respectively, and in 174 and

282 he incidence of in-hospital death (4.1% with abciximab vs. 3.5% with eptifibatide, p = 0.39), recurre

283 A 0.25-mg/kg bolus of abciximab was administered at the site of the infarct le

284 Abciximab was administered by means of a weight-base nom

285 ith intralesional abciximab compared with no abciximab was associated with a lower rate of death (1.4

286 The relative benefit of abciximab was consistent regardless of age, sex, the pre

287 a(3) integrin monoclonal antibody from which abciximab was derived, bound alpha(v)beta(3) on HASMCs i

288 Although combined reteplase and abciximab was not superior to standard reteplase, the 0.

289 Abciximab was reasonably cost-effective (cost-effectiven

290 ticipated interaction between Angioguard and abciximab was seen, with combination therapy better than

291 ment in glomerular filtration rate; although abciximab was superior to placebo (0+/-27% versus -10+/-

292 Abciximab was used in conjunction with recanalization te

293 g with embolic protection, and stenting with abciximab were associated with a decline in glomerular f

294 8758 (P:=0.005) and $9092 (P:=0.176) for the abciximab with low-dose and standard-dose heparin arms,

295 The impact of HPR on clinical outcomes in abciximab with UFH versus bivalirudin treated non-ST-seg

296 For abciximab with UFH, the incidence of the efficacy endpoi

297 wed similar efficacy profiles as compared to abciximab with UFH.

298 myocardial infarction patients that received abciximab with unfractionated heparin (UFH) or bivalirud

299 r better outcomes with tirofiban relative to abciximab, with fewer adverse hematologic and hemorrhagi

300 prising conventional therapy plus a bolus of abciximab within 1 h before PCI followed by a 12-h infus